

## Scientific Letter

### COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom



To the Director,

We are still getting to grip with the impact that COVID-19 pandemic has had on the tuberculosis (TB).<sup>1–3</sup>

The Global Tuberculosis Network (GTN) described the first small cohort of patients with COVID-19 and TB,<sup>4,5</sup> which set the basis for a larger global study.<sup>6</sup> These studies showed that (a) TB can be diagnosed before or after COVID-19, or, quite often, during the same week following radiological examinations and (b) the case fatality rate was rather high (approximately 12%). The evaluation of treatment outcomes of TB of this global cohort and whether there is an interaction is still ongoing as more than half of the patients were still undergoing anti-TB treatment.<sup>6</sup>

The World Health Organization (WHO) in its 2020 Global TB Report<sup>7</sup> predicted, a decrease in TB incidence but increase in TB deaths as a result of the COVID-19 pandemic. In its 2021 Global Report, WHO confirmed the increase in deaths, decrease in notifications, as well as a reduction in access to TB Infection (TBI) treatment. In 2020, 7 million contacts of bacteriologically confirmed pulmonary TB patients were reported to WHO by 126 countries.<sup>8,9</sup> Of these, 3.9 million (55%) in 118 countries were reported as evaluated for both TBI and TB. These numbers were lower than those reported in 2019, by 29% and 31%, respectively.<sup>8,9</sup>

A global GTN Study<sup>10</sup> involving 43 TB centres located in 19 countries in all continents provided further evidence; a decrease in TB disease cases diagnosed: from 32,898 in 2019 to 16,396 in 2020, with reductions in other related metrics during the same period (TB patients discharged from hospital, managed as outpatients, diagnosed with multi-drug resistant TB, etc).

Overall, more information is available for TB disease than for TBI.

Management of TBI is one of the core interventions in the pursuit for TB elimination, as it is focused in preventing the occurrence of active disease and further transmission.<sup>11</sup>

Information on the effects of COVID-19 on diagnosis of TBI in low TB incidence countries is very limited.

The aim of this study was to compare the number of individuals diagnosed with TBI and the number of TBI tests performed in 2020 vs 2019 in 4 low TB incidence European countries: France, Italy, Spain, and the United Kingdom.

Invitations were sent to the GTN TB reference centres previously involved, based on a standardized form (8 in Spain, 5 in Italy and one each for France and the UK).<sup>10</sup>

The coordinating centre and the participating centres had ethics clearance in abundance with their institutional regulations.<sup>10</sup> Data were collected from 1 January 2019 to 31 December 2020 using a standardized form.

The number of new TBI diagnoses and the number of tests performed to diagnose TB infection (tuberculin skin test and interferon- $\gamma$  release assays) were collected monthly.

The results are summarized in [Figs. 1 and 2](#).

Overall, 2397 individuals were diagnosed with TBI in 2019 and 1484 in 2020, as follows: in France 213 and 106, in Italy 1649 and 1023, in Spain 278 and 164 and in the UK 257 and 191, respectively.

The total number of TBI diagnostic tests administered was 16,154 in 2019 and 12,168 in 2020: in France 553 and 341, in Italy 7263 and 5587, in Spain 1323 and 708 and in the UK 7015 and 5532, respectively.

In France, from March 2020 onward the number of individuals diagnosed with TBI was lower than those of 2019 with a marked decline in spring 2020 ([Fig. 1](#)). In October 2020 the number of TBI tests administered had surpassed 2019 figures ([Fig. 2](#)).

In Italy the number of individuals diagnosed with TBI was reduced in spring and autumn 2020 ([Fig. 1](#)), the period corresponding with the first 2 COVID-19 waves, although in autumn 2020 (September and October) more TBI tests were performed than in 2019 ([Fig. 2](#)).

In Spain, a marked decline in the number of individuals diagnosed with TBI was evident during the spring 2020, although in June more diagnoses were done in 2020 than in 2019 ([Fig. 1](#)). The number of TBI tests performed in 2020, with the only exception of June, never exceeded those performed in 2019 ([Fig. 2](#)).

In the UK the marked spring-time decline (first COVID-19 wave) in individuals diagnosed was also present, although more diagnoses were performed in some months of 2020 when compared to 2019 (January, August, September and December) ([Fig. 1](#)). The number of TBI tests performed in 2020 exceeded those performed in 2019 only in February and September ([Fig. 2](#)).

In summary, a marked decline in TBI tests performed and diagnoses was observed in 2020 compared with 2019 in all 4 of the low TB incidence European countries evaluated. This decline corresponded to the stringent lockdown measures and redeployment of healthcare services instituted by these countries during the first COVID-19 wave in 2020.<sup>12</sup> A tentative effort to diagnose TBI more aggressively ([Fig. 2](#)) was performed in autumn 2020, with slight differences relating to the different application of lockdown measures adopted by these countries and the differing characteristics of the reference centres participating.




Fig. 1. Newly diagnosed individuals with tuberculosis infection 2019 vs. 2020, France, Italy, Spain and United Kingdom.




Fig. 2. Number of tests for tuberculosis infection 2019 vs. 2020, France, Italy, Spain and United Kingdom.

The results of this study show the disruption that COVID-19 had on TB services in 2020 (particularly during the first wave, in the absence of vaccines). The disruption included redeployment of human and financial resources to combat COVID-19, implementation of strict lockdown and social distancing measures, stock out of laboratory reagents, and patients fear of accessing health services or access severely restricted or denied due to redeployment of services and lockdown. This phenomenon was more evident for TBI than TB disease, where TBI was deprioritised in favour of managing TB and COVID-19 cases. Lockdowns and the use of masks may have reduced transmission of TB but conversely there may have been increased circulation of *Mycobacterium tuberculosis*, within confined spaces such as households. Because of the disruption of TB services occurred in 2020, more needs to be done to diagnose and treat TBI so that we do not see more TB cases in the years to come, and we can resume the downward trend in TB incidence to elimination.

### Funding

This work was partially funded by the “Ricerca Corrente” scheme of the Ministry of Health, Italy.

### Conflict of interest

The authors declare to have no conflict of interest directly or indirectly related to the manuscript contents.

### Acknowledgments

Collaborators of the Global Tuberculosis Network (by country): *France*: Centre Hospitalier Universitaire, Nantes: Valérie Pascale Bernard. *Italy*: Catholic University of Rome, Rome: Roberto Cauda and Silvia Lamonic; National Institute for Infectious Diseases (INMI) ‘L. Spallanzani’ IRCCS, Rome: Fabrizio Palmieri; University of Sassari, Sassari: Laura Saderi; Tor Vergata University, Rome: Loredana Sarmati and Mirko Compagno; Niguarda Hospital, Milan: Maurizio Ferrarese. *Spain*: Hospital Universitario San Agustín, Avilés: Fernando Álvarez-Navascués and José Antonio Gullón-Blanco; Hospital Universitario Central de Asturias, Oviedo: Marta María García-Clemente; Tuberculosis Research Programme SEPAR, Barcelona: Teresa Rodrigo; Hospital de Cruces, Bilbao; Eva Taberbero. *United Kingdom*: Royal London Hospital of Barts Health National Health Service Trust, London; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London: Christabelle Chen and Susan Dart.

### References

- Visca D, Ong CWM, Tiberi S, Centis R, D’Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. *Pulmonology*. 2021;27:151–65. <http://dx.doi.org/10.1016/j.pulmoe.2020.12.012>.
- McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. *Int J Tuberc Lung Dis*. 2021;25:436–46. <http://dx.doi.org/10.5588/ijtld.21.0148>.
- Dara M, Sotgiu G, Reichler MR, Chiang CY, Chee CBE, Migliori GB. New diseases and old threats: lessons from tuberculosis for the COVID-19 response. *Int J Tuberc Lung Dis*. 2020;24:544–5. <http://dx.doi.org/10.5588/ijtld.20.0151>.
- Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, et al. Active tuberculosis, sequelae and COVID-19 coinfection: first cohort of 49 cases. *Eur Respir J*. 2020;56:2001398. <http://dx.doi.org/10.1183/13993003.01398-2020>.
- Motta I, Centis R, D’Ambrosio L, García-García JM, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology*. 2020;26:233–40. <http://dx.doi.org/10.1016/j.pulmoe.2020.05.002>.
- TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 coinfection: description of the global cohort. *Eur Respir J*. 2022;59:2102538. <http://dx.doi.org/10.1183/13993003.02538-2021>.
- World Health Organization. *Global tuberculosis report 2020*. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- World Health Organization. *Global tuberculosis report 2021*. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- Falzon D, den Boon S, Kanchar A, Zignol M, Migliori GB, Kasaeva T. Global reporting on tuberculosis preventive treatment among contacts. *Eur Respir J*. 2022;59:2102753. <http://dx.doi.org/10.1183/13993003.02753-2021>.
- Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaqui F, et al. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. *Eur Respir J*. 2021;58:2101786. <http://dx.doi.org/10.1183/13993003.01786-2021>.
- Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. *Int J Infect Dis*. 2022. <http://dx.doi.org/10.1016/j.ijid.2022.02.047>. S1201–9712(22)00126–6.
- Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaqui F, et al. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. *J Bras Pneumol*. 2022;48:e20220087. <http://dx.doi.org/10.36416/1806-3756/e20220087>.

José-María García-García<sup>a</sup>, François-Xavier Blanc<sup>b</sup>, Danilo Buonsenso<sup>c</sup>, Rosella Centis<sup>d</sup>, Luigi Ruffo Codecasa<sup>e</sup>, Lia D’Ambrosio<sup>f</sup>, Delia Goletti<sup>g</sup>, Gina Gualano<sup>g</sup>, Heinke Kunst<sup>h</sup>, Emanuele Pontali<sup>i</sup>, Marina Tadolini<sup>j,k</sup>, Simon Tiberi<sup>h</sup>, Catherine W.M. Ong<sup>l,m,n</sup>, Giovanni Sotgiu<sup>o</sup>, Giovanni Battista Migliori<sup>d,\*</sup>, for the Global Tuberculosis Network

<sup>a</sup> Tuberculosis Research Programme (PII-TB) SEPAR, Barcelona, Spain

<sup>b</sup> Nantes Université, CHU Nantes, Department of Respiratory Medicine, L’Institut du thorax, Nantes, France

<sup>c</sup> Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

<sup>d</sup> Respiratory Diseases Clinical Epidemiology Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

<sup>e</sup> TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy

<sup>f</sup> Public Health Consulting Group, Lugano, Switzerland

<sup>g</sup> National Institute for Infectious Diseases (INMI) ‘L. Spallanzani’ - IRCCS, Rome, Italy

<sup>h</sup> Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK

<sup>i</sup> Department of Infectious Diseases, Galliera Hospital, Genoa, Italy

<sup>j</sup> Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

<sup>k</sup> Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

<sup>l</sup> Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>m</sup> Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore

<sup>n</sup> Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore

<sup>o</sup> Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy

Corresponding author.

E-mail address: [giovannibattista.migliori@icsmaugeri.it](mailto:giovannibattista.migliori@icsmaugeri.it) (G.B. Migliori).